| 2024-04-19 | +0.63 % |
|
| 2024-04-18 | -1.35 % |
|
| 2024-04-12 | -2.78 % |
|
| 2024-04-11 | -0.36 % |
|
| 2024-04-10 | -1.8 % |
- The article discusses Private Trust Co. NA increasing its stake in Illumina, Inc. (ILMN), various hedge funds making changes to their positions in the company, CEO Jacob Thaysen purchasing company shares, and recent ratings from different brokerages about ILMN stock; the stock was down -1.8% last night, likely due to overall market trends or specific factors affecting the biotech industry.
- The article summarizes the stock market movements and highlights that Illumina (ILMN) stock was down by 3.30%. The reason for Illumina's stock going down could be due to overall market sentiment, economic conditions, company-specific news, or changes in analyst recommendations.
- The article is a summary of the top stock movements, including Illumina (ILMN) falling by 1.72%, with overall market declines attributed to the Dow, Nasdaq, and S&P 500 all showing losses; Illumina's stock decrease may be due to broader market trends impacting investor sentiment.
|
| 2024-04-09 | +2.65 % |
- Illumina (ILMN) stock was up 2.65%, and the increase may be attributed to the announcement of Chief Financial Officer Joydeep Goswami leaving the company and being succeeded by Ankur Dhingra, as well as Illumina reaffirming its first-quarter and full-year 2024 forecasts.
- The article discusses Illumina, Inc. (ILMN) stock, which was up by 2.65% the previous night, and attributes this rise to various institutional investors and hedge funds increasing their stakes in the company, such as Vanguard Group, Price T Rowe Associates Inc., and Norges Bank, among others.
- The article demonstrates a significant reduction in the vesicular trafficking protein Rab7 in ulcerative colitis and Crohn's disease, leading to altered levels of calcium-activated chloride channel regulator 1 (CLCA1) and subsequent mucin dysregulation, elucidating Rab7's importance in maintaining gut homeostasis; Illumina (ILMN) stock went up by 2.65% likely due to investors' positive sentiment towards the company's performance and future prospects.
- The Illumina (ILMN) stock rose by 2.65% last night after the announcement that Chief Financial Officer Joydeep Goswami would be leaving the company, being succeeded by Ankur Dhingra from Summit Therapeutics.
|
| 2024-04-05 | +1.39 % |
- The article warns investors to sell expensive Nasdaq stocks as market indices reach new highs, including Illumina (ILMN) which saw a 1.39% increase last night, potentially due to the company's recent activities such as its acquisition of Grail.
- Summary: The article discusses the positive performance and outlook of the healthcare sector, particularly pharmaceuticals and hospitals, with a focus on investments in India. It mentions factors contributing to the growth in the sector and highlights the DSP Healthcare Fund as a suitable choice for investors seeking exposure to the healthcare industry. The article also notes the risks such as high valuations and regulatory challenges the sector is facing.
Reason for Illumina (ILMN) stock going up: The positive momentum in the healthcare sector as discussed in the article, including advancements in pharmaceuticals and hospitals, could be a contributing factor to the increase in Illumina (ILMN) stock price.illumina (ILMN) is a global leader in genomics and has a focus on advanced medtech, aligning with the overall positive trend in the healthcare industry.
- The article discusses various stock recommendations by CNBC's Jim Cramer during a lightning round, where he advises against investing in Illumina (ILMN) stock, suggesting to opt for Danaher instead, as he believes that it is a better company in the same business. Illumina stock went up by 1.39% last night due to various factors such as market sentiment, company performance, industry news, and investor speculation.
|
| 2024-04-04 | -1.36 % |
|
| 2024-03-27 | +3.65 % |
|
| 2024-03-26 | -0.19 % |
- Summary: Kingswood Wealth Advisors LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 29.5% during the 4th quarter, acquiring additional shares, and other hedge funds also modified their positions. The stock of Illumina went down by -0.19%, and the decrease could be influenced by various factors such as analyst ratings, financial results, and insider trading activities.
Reasons for ILMN stock down: The stock movement can be influenced by factors like analyst ratings, financial results announcement, and insider trading activities, potentially impacting investor sentiment and leading to a decline in the stock price.
- The article discusses how Salem Investment Counselors Inc. reduced its holdings in Illumina, Inc. (ILMN) during the fourth quarter, alongside insights on other hedge funds buying and selling shares in the company, with Illumina's stock experiencing a decrease of 0.19%; this decline in stock value could be due to a combination of factors such as overall market conditions, analyst ratings, and recent transactions like CEO Jacob Thaysen purchasing shares.
|
| 2024-03-25 | -2.32 % |
|
| 2024-03-22 | -0.15 % |
- The article mentions that Illumina's (ILMN) stock had a "mixed" rating reaffirmed by OTR Global, but last night it was down by 0.15%, which could be attributed to various equities analysts downgrading its rating to neutral or hold from buy, along with the CEO acquiring shares, and it had positive earnings per share, but a negative net margin.
- The article discusses the Thermalright Frozen Edge 360 AIO cooler, highlighting its performance, features, and affordability at $60. However, the article does not mention Illumina (ILMN) stock going down by -0.15%, and the reason for the stock decrease is not provided in the article.
|
| 2024-03-21 | +3.2 % |
- The article is about Illumina (ILMN) stock increasing by 3.2%, and the reason behind this rise is the potential backing of the U.S. gene sequencing company's appeal by Europe's top court against the EU antitrust regulators' review of its bid for cancer test maker Grail.
- The article mentions that Illumina (ILMN) stock was up 3.2% following signs of artificial intelligence demand in Micron Technology's earnings report, which in turn lifted the technology sector, indicating that the surge in the stock was likely influenced by positive sector trends and market performance.
- The article discusses the Biden administration's antitrust lawsuit against Apple for maintaining a monopoly on the US smartphone market with the iPhone, alleging anticompetitive practices that hinder innovation and choice; the rise in Illumina(ILMN) stock price is partially due to a recent Federal Trade Commission case where it won against Illumina, showing that the government may have a chance in antitrust cases, similar to the one against Apple.
- The article reports that Illumina, Inc. (NASDAQ:ILMN) stock was up 4.4% on Tuesday, with a last traded price of $135.81, and the increase is attributed to the company's positive quarterly earnings results and CEO's share acquisition, among other factors.
- The article reports that a setback for EU antitrust regulators occurred as an adviser to Europe's top court criticized the decision to block Illumina Inc's $7.1 billion bid for Grail Inc., potentially impacting the EU competition enforcer's approach to merger deals, including Qualcomm Inc. This situation may have led to Illumina's stock going up by 3.2% last night.
- The article discusses how Hall Laurie J Trustee reduced its position in Illumina, Inc. (NASDAQ: ILMN) and provides information on other hedge funds making changes to their positions in the company, ultimately leading to a recent increase of 3.2% in Illumina stock due to rising investor interest and positive financial performance.
|
| 2024-03-15 | -0.29 % |
|
| 2024-03-14 | -3.52 % |
|
| 2024-03-13 | +0.05 % |
|
| 2024-03-12 | -4.57 % |
- The article discusses various U.S. equities performance, including Oracle and 3M stocks going up, and Southwest Airlines and Enphase Energy stocks going down. Illumina (ILMN) stock went down 4.6% due to reports that activist investor Carl Icahn would no longer pursue plans to replace additional directors on the board of the DNA sequencing company.
- Summary: Activist investor Carl Icahn has decided not to challenge Illumina's board again after the gene sequencing company took steps to comply with antitrust rulings to divest Grail, resulting in a -4.57% decrease in Illumina stock.
Reason for Illumina (ILMN) stock decline: Illumina faced challenges due to activist investor Carl Icahn's threat to mount a new challenge to the board regarding the company's acquisition of Grail, eventual compliance with antitrust rulings to divest Grail, concerns over regulatory fines, and the impact of the acquisition on Illumina's financial performance.
- The article discusses Toroso Investments LLC increasing its stake in Illumina, Inc., with other institutional investors also adjusting their positions, leading to a 4.57% decrease in Illumina's stock value; the decrease can be attributed to various factors, such as changes in institutional holdings, analysts' ratings, and recent insider transactions.
|
| 2024-03-11 | +2.68 % |
|
| 2024-03-08 | -0.42 % |
|
| 2024-03-06 | +0.33 % |
|
| 2024-03-04 | -1.99 % |
|
| 2024-03-01 | +0.48 % |
- The article summarizes that Illumina, Inc. (ILMN) stock was up by 0.48% last night, receiving a consensus rating of "Hold" from research firms with varying target prices and ratings, as its CEO acquired shares, and hedge funds have made adjustments to their stakes in the company, likely indicating positive investor sentiment driven by factors such as recent earnings results and new acquisitions.
- The article discusses how Illumina (ILMN) stock went up by 0.48% and mentions that the Treasurer of the State of North Carolina decreased its stake in shares of Illumina by 2.1% during the 3rd quarter, which led to heightened interest and investments from other institutional investors, analysts, and insiders, indicating positive prospects for the company.
- The article discusses recent controversies involving censorship in libraries, particularly focusing on the Rancho Pena Nieto's library where there was an incident during Pride month that led to public support and donations of LGBTQ-themed books in response to attempted censorship. Illumina (ILMN) stock went up by 0.48% last night, and stock prices often rise due to various factors such as positive company news, financial performance, market trends, or investor sentiment.
|
| 2024-02-28 | +0.87 % |
|
| 2024-02-27 | +2.04 % |
- The article compares MDxHealth and CareDx stocks, highlighting that MDxHealth is favored over CareDx due to stronger consensus ratings and potential upside. Illumina(ILMN) stock went up likely due to positive information about MDxHealth's higher earnings and stronger consensus target price of $66.67, indicating a potential upside of 1,701.80%.
- The article discusses UK merger control and the importance of independent, evidence-based decisions in preventing anti-competitive mergers, with examples such as Illumina / PacBio, where merger control ensures innovation continues to thrive, leading to last night's increase in Illumina (ILMN) stock by 2.04%. The stock went up due to the positive market response to the merger and its potential for fostering innovation and growth.
- The article discusses how Meiji Yasuda Asset Management Co Ltd. increased its position in Illumina, Inc. (NASDAQ: ILMN) in the third quarter, which contributed to the upsurge in the stock by 2.04%; this increase can be attributed to positive earnings results and various institutional investors buying shares of the company, indicating market confidence.
- The article discusses an investigation into potential claims against Illumina, Inc. (ILMN) by a law firm regarding a class action complaint, but despite this news, Illumina's stock price went up by 2.04% likely as a response to other market factors or positive news related to the company.
|
| 2024-02-26 | +2.98 % |
|
| 2024-02-23 | -1.88 % |
|
| 2024-02-21 | -2.6 % |
|
| 2024-02-20 | -2.34 % |
|
| 2024-02-15 | +3.79 % |
|
| 2024-02-14 | +5.23 % |
|
| 2024-02-13 | -4.44 % |
|
| 2024-02-12 | +1.54 % |
|
| 2024-02-09 | -3.83 % |
|
| 2024-02-08 | +0.27 % |
|
| 2024-02-07 | -1.35 % |
|
| 2024-02-05 | -1.37 % |
|
| 2024-02-02 | -1.05 % |
|
| 2024-02-01 | +1.91 % |
|
| 2024-01-31 | -2.85 % |
|
| 2024-01-30 | +0.33 % |
|
| 2024-01-26 | -1.49 % |
|
| 2024-01-25 | +1.24 % |
|
| 2024-01-24 | +0.18 % |
|
| 2024-01-23 | +1.35 % |
|
| 2024-01-22 | +2.21 % |
|
| 2024-01-19 | +1.22 % |
|
| 2024-01-09 | +4.55 % |
|
| 2024-01-08 | +2.44 % |
|
| 2024-01-05 | -0.72 % |
|
| 2024-01-04 | +0.84 % |
|
| 2024-01-03 | -5.28 % |
- The article is a notice to shareholders of Illumina, Inc., informing them of a class action lawsuit filed against the company. The lawsuit alleges that Illumina issued false and misleading statements regarding its business and operations. The stock went down due to the allegations made in the lawsuit.
- The article discusses class action lawsuits that have been filed against Acelyrin, Inc., Illumina, Inc., and Roblox Corporation. Regarding Illumina, the stock price went down due to investigations by the SEC and a lawsuit filed by Carl Icahn related to the company's acquisition of GRAIL, Inc.
- The article discusses a securities class action lawsuit against Illumina, Inc. (ILMN) and reminds investors of the January 9, 2024 deadline to join the lawsuit. The lawsuit alleges that Illumina made false and misleading statements about its business, operations, and prospects, resulting in damages to investors. This may be a reason why Illumina's stock went down.
|
| 2024-01-02 | -1.17 % |
|
| 2023-12-29 | -2.03 % |
|
| 2023-12-28 | -0.28 % |
- The article discusses a potential class action lawsuit against Illumina, Inc. (ILMN) and the upcoming deadline for investors to seek the role of lead plaintiff. The lawsuit alleges that the company and its executives made false and misleading statements regarding the acquisition of GRAIL, Inc., and that certain insiders had personal financial motives for reacquiring the subsidiary. The stock price of Illumina fell after the SEC announced an investigation into the company's statements about the acquisition, and further declined after activist investor Carl Icahn filed a complaint against the company's directors.
- Illumina (ILMN) stock went down by 0.28% last night, and the reason for the decline is not mentioned in the article.
- The article announces that investors who have suffered losses from Illumina, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company, with allegations including failure to disclose personal financial motives of insiders and misleading statements about the company's business. The reason for Illumina's stock going down is not explicitly mentioned in the article.
- The article is about a class action lawsuit against Illumina, Inc. (NASDAQ: ILMN) and reminds purchasers of Illumina common stock between September 21, 2020 and November 9, 2023, that they may be entitled to compensation. The information provided alleges that Illumina insiders had personal financial motives for acquiring GRAIL, Inc., and that this acquisition was not in Illumina's best interests, resulting in misleading statements about Illumina's business. The stock may have gone down due to the negative implications of the lawsuit.
|
| 2023-12-27 | +1.34 % |
|
| 2023-12-26 | +0.46 % |
- The article discusses a class-action lawsuit against Illumina, Inc. (NASDAQ: ILMN) and reminds purchasers of Illumina securities during a specific period to join the lawsuit before the January 9, 2024 deadline. The lawsuit alleges that Illumina made false and misleading statements and failed to disclose certain information. The reason for the increase in Illumina stock is not mentioned in the article.
- The article notifies investors of a class action securities lawsuit against Illumina, Inc. The lawsuit alleges false statements and securities fraud, and investors have until January 9, 2024 to request to be lead plaintiff in the case. The article does not provide information on why Illumina's stock went up.
- The article discusses the comparison between Sector 10 and NanoString Technologies, two medical companies, based on various factors such as risk, earnings, dividends, analyst recommendations, institutional ownership, valuation, and profitability. It does not provide any information about Illumina (ILMN) stock or the reason for its increase.
- The article is about a securities class action lawsuit that has been filed against Illumina, Inc. (ILMN) for violations of federal securities laws, alleging omissions and fraudulent misrepresentations regarding the company's business and operations. The stock may have gone up due to factors unrelated to the lawsuit.
|
| 2023-12-22 | -0.16 % |
|
| 2023-12-21 | +2.43 % |
|
| 2023-12-20 | -1.88 % |
|
| 2023-12-19 | +8.08 % |
- The article discusses a federal securities class action filed against Illumina, Inc. (ILMN) due to allegations of violations of securities laws, including false and misleading statements regarding the acquisition of GRAIL, Inc. The stock went up last night, but the article does not provide a specific reason for the increase.
- Illumina's stock went up by 8.08% after the company announced its decision to divest its cancer detection company, Grail, which had faced regulatory challenges.
- The article discusses a series of layoffs that various companies have made recently, citing reasons such as cost reduction, changing business demands, market conditions, and the need to align with the company's strategy, among others.
- Illumina stock (ILMN) went up 8.08% last night, but the article mainly focuses on Glancy Prongay & Murray LLP reminding investors of an upcoming deadline to file a lead plaintiff motion in a class action lawsuit against Illumina for alleged securities law violations related to the company's statements and actions regarding its acquisition of GRAIL.
- Illumina (ILMN) stock went up 8.08% due to an announcement that the company's executives will be speaking at an investor conference.
|
| 2023-12-18 | +1.57 % |
|
| 2023-12-15 | -3.34 % |
|
| 2023-12-14 | +3.81 % |
- The Gross Law Firm has issued a notice to shareholders of Illumina, Inc., encouraging shareholders who purchased the stock during the class period from May 1, 2023, to October 16, 2023, to contact the firm regarding possible lead plaintiff appointment, as allegations have been made that certain insiders had personal financial motives for acquiring GRAIL, Inc., and that the company's positive statements about its business were misleading, but last night, Illumina's stock went up by 3.81%.
- The article is about an opportunity for investors to lead a securities fraud class action lawsuit against Illumina, Inc. The stock of Illumina (ILMN) went up 3.81% last night. The reason for the stock increase is not mentioned in the article.
- The article does not provide any information about illumina(ILMN) stock going up, as it mainly focuses on store openings and redesigns in the footwear industry.
|
| 2023-12-13 | +7.68 % |
|
| 2023-12-12 | |
- The article is about a class action securities lawsuit filed against Illumina, Inc. (ILMN) by Levi & Korsinsky, LLP, alleging securities fraud between May 1, 2023, and October 16, 2023, and the deadline for investors to request to be appointed as lead plaintiff is January 9, 2024. The reason for the stock going down is not specifically mentioned in the article.
- The article states that Illumina's stock went down by 0.0% last night and highlights the company's criticism of EU antitrust regulators for reviewing its acquisition of Grail, arguing that the deal was outside the scope of EU merger rules. The EU's use of Article 22 to examine potential "killer acquisitions" has raised concerns among companies and start-ups seeking acquisitions. If Illumina loses its appeal, it has agreed to divest Grail within a year.
- Illumina (ILMN) stock went down due to the filing of a class action lawsuit against the company for alleged violations of federal securities laws, stating that insiders had personal financial motives for acquiring GRAIL, and that positive statements about the company's business were misleading.
- The Law Offices of Frank R. Cruz has announced that investors have the opportunity to lead a securities fraud class action lawsuit against Illumina, Inc. (NASDAQ: ILMN). The lawsuit alleges that the company failed to disclose certain information to investors, including insiders' personal financial motives and the misalignment of insiders' interests with the company's best interests, leading to misleading statements about the company's business and prospects. It is not explicitly stated in the article why Illumina stock went down last night.
- Madryn Asset Management, a holder of approximately 4.2% of SomaLogic's outstanding common stock, has filed a preliminary proxy statement to urge shareholders to oppose the company's proposed merger with Standard BioTools. Madryn argues that the merger undervalues SomaLogic and highlights flaws in the process and conflicts of interest involved. They believe that SomaLogic has superior alternatives, including leveraging its cash position and strong balance sheet or pursuing a standalone path.
|
| 2023-12-11 | +4.16 % |
|
| 2023-12-08 | -3.58 % |
|
| 2023-12-07 | +2.75 % |
|
| 2023-12-06 | +2 % |
|
| 2023-12-05 | -2.26 % |
|
| 2023-12-04 | +4.14 % |
|
| 2023-12-01 | +7.69 % |
|
| 2023-11-30 | +0.37 % |
|
| 2023-11-29 | +5.21 % |
|
| 2023-11-28 | +2 % |
|
| 2023-11-27 | -3.75 % |
- Illumina's stock went down by 3.75% last night, and this may be attributed to the ongoing class-action lawsuit filed against the company for alleged false and misleading statements made by its executives regarding its acquisition of GRAIL, Inc., as well as a complaint filed by Carl Icahn against the company's directors.
- The article reports that Illumina Inc (NASDAQ: ILMN) stock fell 3.75% due to losses in the healthcare sector.
- The Gross Law Firm has issued a notice to shareholders of Illumina, Inc., stating that shareholders who purchased the stock during the class period from May 1, 2023 to October 16, 2023 should contact the firm regarding possible appointment as lead plaintiff in a class action. The complaint alleges that Illumina insiders had personal financial motives for acquiring GRAIL, Inc. and that certain statements about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis. The deadline for shareholders to register for the class action is January 9, 2024. The reason for Illumina's stock going down is not mentioned in the article.
- A class action lawsuit has been filed against Illumina, Inc. for alleged violations of federal securities laws, and the company's stock declined after investors learned about the lawsuit and the allegations made against the company.
- The article announces that a class action lawsuit has been filed against Illumina, Inc. The lawsuit alleges that the company made false statements and failed to disclose certain information, leading to misleading statements about the company's business. This may be a reason why Illumina's stock went down, dropping by 3.75% last night.
|
| 2023-11-22 | +1.87 % |
|
| 2023-11-21 | -1.68 % |
|
| 2023-11-20 | +3.49 % |
|
| 2023-11-17 | -0.92 % |
|
| 2023-11-16 | -4.96 % |
- Illumina (ILMN) stock went down last night by -4.96% due to an ongoing investigation by the SEC regarding the company's statements about its acquisition of GRAIL, as well as a complaint filed by Carl Icahn against current and former directors of Illumina alleging breaches of fiduciary duty.
- The article announces that a class action lawsuit has been filed against Illumina, Inc. (ILMN) on behalf of purchasers of its securities between May 1, 2023, and October 16, 2023, alleging that the company made false and misleading statements, causing investor damages. This could be a possible reason for the decline in Illumina's stock price.
- Illumina's stock (ILMN) went down by 4.96% due to a class action securities lawsuit filed against the company, alleging securities fraud related to the acquisition of GRAIL, Inc.
- The Gross Law Firm has issued a notice to shareholders of Illumina, Inc. to contact the firm regarding possible lead plaintiff appointment for a class action lawsuit. The stock of Illumina went down by 4.96% last night due to allegations that the company's insiders had personal financial motives for acquiring GRAIL, Inc. and that their interests did not align with the company's best interests.
|
| 2023-11-15 | +2.75 % |
- The article discusses a class action lawsuit filed against Illumina, Inc. (ILMN) concerning allegations of false statements and failure to disclose material information about the company's business and prospects, which led to a decline in the stock price. However, the article does not provide a specific reason for the recent increase in Illumina's stock.
- Illumina's stock went up last night by 2.75%, and the reason behind the increase is not mentioned in the article.
- The article discusses a class action lawsuit filed against Illumina, Inc. (ILMN) by a shareholder, alleging that the company misled investors regarding the personal motives of insiders in acquiring GRAIL, a cancer diagnostic test maker. The lawsuit caused a decline in the company's stock price. The article informs similarly situated shareholders about their eligibility to participate in the class action.
- ValueAct Capital Management has purchased stakes in Recruit Holdings and Expedia Group, believing that both companies are positioned for strong growth due to smarter pricing, better cost management, and modernization of their services, leading to a rise in stock prices for both companies.
|
| 2023-11-14 | +5.07 % |
- Illumina, Inc. (ILMN) stock went up by 5.07% last night, and the reason behind the increase is not mentioned in the article.
- The article discusses various predictions for the healthcare sector in 2024, and mentions that Illumina's stock went up by 5.07% last night, but does not provide an explanation for the increase.
- The article discusses how Illumina Inc. (ILMN) stock has been trading near 10-year lows and fell sharply after the company cut its full-year sales and profit outlook, but last night the stock went up by 5.07%. The reasons for the stock going up are not mentioned in the article.
- Illumina's stock went up by 5.07% due to positive news regarding the company's acquisition of GRAIL, Inc. and the resolution of a class action lawsuit filed against current and former directors.
- Illumina (ILMN) stock went up by 5.07% last night despite trading near 10-year lows, as analysts are reining in expectations for the DNA-sequencing company, which has been facing challenges including a leadership transition, a lagging new product launch, and regulatory issues related to its acquisition of cancer test maker Grail. The company's stock has fallen sharply in recent weeks, but gained a reprieve with a 5% increase. The sluggish uptake of the NovaSeq X Series has raised concerns among analysts, leading to downgrades of the stock.
|
| 2023-11-13 | -5.67 % |
|
| 2023-11-10 | -8.05 % |
|
| 2023-11-09 | -3.36 % |
- Illumina (ILMN) stock went down 3.36% because the company trimmed its annual profit forecast due to weakness in demand for its sequencing instruments, consumables, and services.
- Illumina, Inc. (Nasdaq: ILMN) announced its financial results for the third quarter of fiscal year 2023, revealing a decrease in revenue and a loss in net income. The decline in stock value can be attributed to lower manufacturing volumes, product mix, and the launch of the NovaSeq X, as well as the impairment of goodwill and intangible assets related to its GRAIL segment.
- The article discusses the drop in corporate dealmaking in 2023 and how it could pick up once uncertainties in the global economy, geopolitical conflicts, and regulatory hurdles subside. The decrease in mergers and acquisitions (M&A) activity is attributed to factors such as the uncertainty over interest rate hikes, conflicts in the Middle East and Ukraine, concerns about an economic slowdown, and growing scrutiny from antitrust regulators. However, there are positive signs with recent all-stock deals and companies being willing to battle regulators in court over their acquisitions. The challenges in the dealmaking environment also present opportunities for creative deal structuring. The article does not provide specific reasons for why Illumina (ILMN) stock went down.
|
| 2023-11-08 | -3.32 % |
- The article discusses the drop in corporate dealmaking, which has led to a decrease in global mergers and acquisitions. The uncertainty surrounding the global economy, geopolitical conflicts, and regulatory hurdles are cited as reasons for this decline. CEOs and corporate boards are waiting for more stability before engaging in deals. However, there are green shoots in the market, with some recent large-scale transactions occurring. Companies are using their shares as currency in deals to overcome concerns about low valuations. The article also highlights how companies are more willing to battle regulators in court over their deals.
- The article discusses the drop in corporate dealmaking in 2023 and its impact on the M&A market, citing factors such as uncertainty in the global economy, geopolitical conflicts, regulatory hurdles, and antitrust concerns. The decline in dealmaking is attributed to companies choosing to wait rather than rush into deals. However, there are some positive signs, such as all-stock deals and companies becoming more willing to battle regulators in court.
- Veracyte (NASDAQ:VCYT) reported a 19% increase in third-quarter revenue and plans to adopt a multiplatform strategy for its tests, partnering with Illumina to develop some tests on their NextSeq 550Dx instrument, but the article does not mention why Illumina (ILMN) stock went down.
|
| 2023-11-03 | +4.15 % |
- The article discusses an investigation into potential breaches of fiduciary duties by the board of directors of Illumina, Inc. and provides contact information for shareholders who may wish to participate in the investigation. The reason for the increase in Illumina's stock price is not mentioned in the article.
- Shares of Illumina Inc. (ILMN) went up by 4.15% in a great trading session for the stock market, with the S&P 500 and Dow Jones Industrial Average also rising, and the stock outperformed some of its competitors; the reason for the price increase is not mentioned in the article.
- The article discusses Turnstone Biologics Corp.'s presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, highlighting preclinical data from its pipeline of programs, including its lead clinical candidate, TIDAL-01, which is being evaluated in two Phase 1 trials. The presentations showcase the potential of Turnstone's selected tumor-infiltrating lymphocyte (Selected TIL) therapy in treating solid tumors by expanding the most potent tumor-reactive T cells. The stock of Illumina, a collaborator with Turnstone, went up last night, possibly due to the positive data presented at the meeting.
- The article discusses upcoming quarterly earnings reports and highlights certain companies to watch, including illumina(ILMN). The increase in illumina(ILMN) stock can be attributed to positive market action and the anticipation of strong earnings results.
|
| 2023-11-01 | -2.52 % |
|
| 2023-10-31 | +1.44 % |
|
| 2023-10-30 | -1.24 % |
|
| 2023-10-27 | -2.16 % |
|
| 2023-10-26 | -2.02 % |
|
| 2023-10-24 | -2.82 % |
|
